Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit

Caving in to opposition from the Federal Trade Commission, CSL Limited has scuttled its $3.1 billion deal to acquire Talecris Biotherapeutics, saying it was not worth the money and time to battle the agency in court